论文部分内容阅读
[目的]探讨围术期不同抗血小板方案治疗颅内未破裂动脉瘤介入术患者临床疗效及出血风险比较.[方法]回顾性分析2012年2月至2016年10月本院收治的160例颅内未破裂动脉瘤行介入术治疗的患者的临床资料,根据治疗方法不同将其分为A组[术中给予负荷剂量(8μg/kg)替罗非班治疗,3 min后改为维持剂量(0.1μg/kg·min)治疗,n =50]、B组(术前2~24 h给予负荷剂量氯吡格雷治疗,n =60)、C组(术前3~5 d给予75 mg氯吡格雷+100 mg阿司匹林治疗,n =50),观察三组术后出血事件及血栓栓塞事件发生率、并发症发生率、格拉斯哥昏迷指数(GOS)评分变化及半年后随访预后情况.[结果]术后A组出血事件及血栓栓塞事件发生率显著低于B组、C组,差异有统计学意义(均 P 0.05).术后A组并发症发生率显著低于B组、C组,差异有统计学意义(P 0.05).治疗前,三组GOS评分比较,差异无统计学意义(P >0.05);术后1个月、术后2个月、术后3个月三组GOS评分显著高于治疗前,且A组GOS评分显著高于B组、C组,差异均具有统计学意义(P 0.05).At 1 month,2 months and 3 months after operation,the GOS scores of the three groups were significantly higher,and the increase was more obvious in A group than B group and C group(P 0.05).The follow-up rate was 100%(50/50)in group A,98.33(59/60)in group B,and 96.00(48/50)in group C.The follow-up results showed that the prognosis of group A was significantly better than group B and group C;the difference was statistically significant(P <0.05).[Conclusion]Tirofiban regimen can be used as a safe and effective antiplatelet treatment for patients with unruptured intracranial aneurysms treated by interventional therapy.Compared with dual antiplatelet regimen and loading dose of clopidogrel regimen,it has more advantages,and the risks of bleeding are lower.